Antigen expression and treatment results with monoclonal antibodies in acute lymphocytic leukemia (ALL).
| Antigen . | Expression on >20%a . | Clinical Application Antibody . | Stage . | n . | Tx . | Results . | Author . |
|---|---|---|---|---|---|---|---|
| a Data from the GMALL (German Multicenter Studies for Adult ALL) central immunophenotyping, E.Thiel, S.Schwartz et al, Berlin, Germany. | |||||||
| CD19 | 95% B-precursor | AntiCD19+PAP | de novo child | 14 | CH | 43% CR d14 | Seibel et al 41 |
| 94% Mature B-ALL | 14 | AB+CH | 93% CR d14 | ||||
| AntiCD19+Ricin | de novo adult | 46 | AB+CH | No effect on MRD | Szatrowski et al 42 | ||
| AntiCD19+Genistein | ref/rel child | 15 | AB | 2 CR, 2 PR | Messinger et al 43 | ||
| CD20 | 41% B-precursor | Rituximab | de novo adult | 19 | AB+CH | 93% CR | Thomas et al 29 |
| 86% Mature B-ALL | 86% OS 1y | ||||||
| CD52 | 66% B-/T-lineage | Campath | ref/rel. adult | 5 | AB | 0 CR, 0 PR | Faderl et al 44 |
| Antigen . | Expression on >20%a . | Clinical Application Antibody . | Stage . | n . | Tx . | Results . | Author . |
|---|---|---|---|---|---|---|---|
| a Data from the GMALL (German Multicenter Studies for Adult ALL) central immunophenotyping, E.Thiel, S.Schwartz et al, Berlin, Germany. | |||||||
| CD19 | 95% B-precursor | AntiCD19+PAP | de novo child | 14 | CH | 43% CR d14 | Seibel et al 41 |
| 94% Mature B-ALL | 14 | AB+CH | 93% CR d14 | ||||
| AntiCD19+Ricin | de novo adult | 46 | AB+CH | No effect on MRD | Szatrowski et al 42 | ||
| AntiCD19+Genistein | ref/rel child | 15 | AB | 2 CR, 2 PR | Messinger et al 43 | ||
| CD20 | 41% B-precursor | Rituximab | de novo adult | 19 | AB+CH | 93% CR | Thomas et al 29 |
| 86% Mature B-ALL | 86% OS 1y | ||||||
| CD52 | 66% B-/T-lineage | Campath | ref/rel. adult | 5 | AB | 0 CR, 0 PR | Faderl et al 44 |